此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Atherosclerosis in Early Rheumatoid Arthritis Patients Using Atherogenic Index of the Plasma and Carotid Intima Media Thickness

2026年8月16日 更新者:Shenouda Heshmat Abdou、Assiut University

Atherogenic Index of Plasma and Carotid Intima-media Thickness as Predictors of Preclinical Atherosclerosis in Early Rheumatoid Arthritis Patients Younger Than 50 Years of Age

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease primarily affecting the peripheral joints, yet its extra-articular burden particularly on the cardiovascular (CV) system has emerged as its most consequential long-term complication . Cardiovascular disease (CVD) accounts for 40% of all deaths in RA patients, making it the leading cause of mortality .This excess CV risk is estimated to be 1.5 to 2 times higher than in the general population .The overall CV risk conferred by RA has been linked in magnitude to that of diabetes mellitus, underscoring RA as an independent cardiovascular risk factor formally recognised in the 2021 European Society of Cardiology Guidelines on CVD prevention .

In this context, the non-invasive detection of preclinical atherosclerosis before the onset of clinical CV events has become clinical priority. Carotid intima-media thickness (CIMT), measured by high-resolution B-mode ultrasonography, is a well-validated surrogate marker of early structural arterial wall changes that independently predicts future myocardial infarction and stroke .Multiple studies have documented significantly elevated CIMT in RA patients compared with age- and sex-matched controls; studies found higher CIMT values across all age groups in RA, with values increasing in proportion to disease severity as assessed by the Disease Activity Score in 28 joints .

The atherogenic index of plasma (AIP) defined as the base-10 logarithm of the triglyceride-to-HDL-cholesterol ratio has emerged as a calculated composite biomarker reflecting lipoprotein particle atherogenicity, particularly the preponderance of small, dense LDL particles .A high AIP (>0.21) has been independently associated with major adverse cardiovascular events beyond the predictive capacity of conventional lipid panels .

研究概览

地位

尚未招聘

研究类型

观察性的

注册 (估计的)

70

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

不适用

取样方法

非概率样本

研究人群

adult patients presented to rheumatology department with early rheumatoid arthritis

描述

Inclusion Criteria:

for cases (Rheumatoid Arthritis patients)

  • Patients fulfilling the 2010 American College of Rheumatology / European League Against Rheumatism (ACR/EULAR) classification criteria for RA
  • Disease duration of ≤6 months from the onset of symptoms (early RA)

For Controls (Healthy Subjects):

  • Healthy volunteers aged 18 to 49 years with no known inflammatory, autoimmune, or chronic disease.
  • Age- and sex-matched (within ±2 years) to case subjects

Exclusion Criteria:

  • Established cardiovascular disease (coronary artery disease, prior myocardial infarction, stroke, peripheral arterial disease, or heart failure).
  • Diabetes mellitus, Hypertension, and Dyslipidaemia on lipid-lowering therapy (statins, fibrates, niacin, or omega-3 agents), as these agents directly modify AIP values.
  • Chronic kidney disease (eGFR <60 mL/min/1.73 m²) and Hepatic disease, thyroid dysfunction, or any other significant endocrine disorder.
  • Pregnancy or lactation.
  • Other connective tissue diseases (systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome).
  • Other inflammatory arthropathies (psoriatic arthritis, ankylosing spondylitis, reactive arthritis).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
early Rheumatoid arthritis patients younger than 50 years of age

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
atherosclerosis assessment in early diagnosed Rheumatoid Arthritis
大体时间:• Disease duration of ≤6 months from the onset of symptoms
  • Mean Atherogenic Index of Plasma Unitless (ratio / calculated index)
  • Mean Carotid Intima-Media Thickness measured in mm via ultrasonography
• Disease duration of ≤6 months from the onset of symptoms

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2028年5月1日

研究完成 (估计的)

2028年12月30日

研究注册日期

首次提交

2026年8月9日

首先提交符合 QC 标准的

2026年8月16日

首次发布 (实际的)

2026年8月19日

研究记录更新

最后更新发布 (实际的)

2026年8月19日

上次提交的符合 QC 标准的更新

2026年8月16日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅